Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-grade Serous Ovarian Carcinoma (LGSOC)”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Looking for participantsNCT04111978
What this trial is testing

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Who this might be right for
Ovarian Neoplasm EpithelialFallopian Tube NeoplasmsPeritoneal Neoplasms+3 more
Swiss GO Trial Group 540
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 54
Large-scale testing (Phase 3)Looking for participantsNCT06072781
What this trial is testing

Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Who this might be right for
Low Grade Serous Ovarian Cancer
Verastem, Inc. 270
Testing effectiveness (Phase 2)Active Not RecruitingNCT06682572
What this trial is testing

Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Who this might be right for
Low Grade Serous Ovarian CancerOvarian Cancer
Verastem, Inc. 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270
What this trial is testing

Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Verastem, Inc. 225